60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a research report issued on Friday,Benzinga reports.

60 Degrees Pharmaceuticals Price Performance

Shares of NASDAQ:SXTP opened at $1.05 on Friday. The firm’s 50 day simple moving average is $1.19 and its 200 day simple moving average is $0.99. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $13.20. The company has a market capitalization of $2.41 million, a price-to-earnings ratio of -0.10 and a beta of 4.40.

Insiders Place Their Bets

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow bought 35,823 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average cost of $1.27 per share, with a total value of $45,495.21. Following the transaction, the chief executive officer now directly owns 94,580 shares in the company, valued at $120,116.60. This trade represents a 60.97 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought a total of 66,372 shares of company stock valued at $82,410 in the last 90 days. 10.27% of the stock is currently owned by corporate insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.